# Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

> **NCT05553522** · PHASE1 · TERMINATED · sponsor: **Baptist Health South Florida** · enrollment: 1 (actual)

## Conditions studied

- Brain Metastases
- HER2-positive Breast Cancer

## Interventions

- **COMBINATION_PRODUCT:** Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine

## Key facts

- **NCT ID:** NCT05553522
- **Lead sponsor:** Baptist Health South Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-29
- **Primary completion:** 2025-12-17
- **Final completion:** 2025-12-17
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Slow enrollment
- **Last updated:** 2025-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05553522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05553522, "Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05553522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*